Echo ラーニングセンター

Echo ラーニングセンター

Better + Together. 2019年、ベックマン・コールターライフサイエンスとLabcyteが一緒になったことで、Echoリキッドハンドラーの音響分注によってもたらされるパワーとBiomek自動ワークステーションの技術が統合され、創薬、サンプルマネジメント、合成生物学、ジェノミクス、プロテオミクス、ファンクションスクリーニングなどのワークフローにおいて、複雑な液体分注にも対応できる柔軟なリキッドハンドラーという、新たなソリューションが誕生しました。

音響エネルギーによる、最小2.5 nL での高精度、非接触、自動化の微量分注機です。未体験の正確性、高効率、持続可能性をEchoアコースティック微量分注機でお確かめください。

Echo Acoustic Liquid Handlers - Beckman Coulter Life Sciences

音響による液体分注

 

Echoアコースティック微量分注機は

  • アコースティックドロップエジェクション（ADE）技術の搭載により、正確かつ高速での分注が実現（最大700ドロップ/秒）
  • Echoソースプレート（下側）から（反転させた上側の）ディスティネーションプレートへ非接触分注
  • ダイナミックフルードアナリシス（DFA）がパラメータをリアルタイム調整し、ナノリットルレベルでも信頼性の高い分注が可能（ユーザによる調整不要）
  • 各ウェル中の液体の高さを計算、溶液タイプ（DMSO等）やグリセロール濃度も分析
  • 1:1、1:複数ウェル、複数ウェル:1での分注や、ソースプレートからディスティネーションプレートのドライウェル、あるいはプレフィルドウェルなどの複雑な組み合わせ分注が可能

さらに詳しい情報はこちらから

カタログ

Download ↓Echo Liquid Handler Brochure Cover
Download ↓Automated Liquid Handling for Drug Discovery Brochure Cover
Download ↓Echo Software Applications Brochure Cover
Download ↓Echo Qualified Consumables Brochure Cover
Download ↓Full Care Lease-to-Own Program flyer

動画

Echoアコースティック微量分注機　製品モデル

 

Echoソフトウエア

 

Echo関連文献

  1. Bashore C et al. Targeted degradation via direct 26S proteasome recruitment. Nat Chem Biol. 2023 Jan;19(1):55-63. Epub 2022 Dec 28. PMID: 36577875
  2. Ma S et al. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer. Nat Commun. 2022 Feb 25;13(1):1061. PMID: 35217640
  3. Pal R, Seleem MN. Discovery of a novel natural product inhibitor of Clostridioides difficile with potent activity in vitro and in vivo. PLoS One. 2022 Aug 8;17(8):e0267859. PMID: 35939437
  4. Papandreou A et al. Automated High-Content Imaging in iPSC-derived Neuronal Progenitors. SLAS Discov. 2023 Jan 4:S2472-5552(22)13715-9. PMID: 36610640
  5. Riva L et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020 Oct;586(7827):113-119. Epub 2020 Jul 24. PMID: 32707573
  1. Li J et al. DRUG-seq Provides Unbiased Biological Activity Readouts for Neuroscience Drug Discovery. ACS Chem Biol. 2022 Jun 17;17(6):1401-1414. Epub 2022 May 4. PMID: 35508359
  2. Nyffeler J et al. Combining phenotypic profiling and targeted RNA-Seq reveals linkages between transcriptional perturbations and chemical effects on cell morphology: Retinoic acid as an example. Toxicol Appl Pharmacol. 2022 Jun 1;444:116032. Epub 2022 Apr 26. PMID: 35483669
  1. Bousgouni V, Bakal C. Quantitative imaging of single-cell phenotypes in cancer cells cultured on hydrogel surfaces. STAR Protoc. 2022 Dec 15;4(1):101942. doi: 10.1016/j.xpro.2022.101942. Epub ahead of print. PMID: 36525347
  2. Denisova OV et al. Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells. Sci Rep. 2022 Aug 13;12(1):13796. doi: 10.1038/s41598-022-18118-7. PMID: 35963891
  3. Ross-Thriepland D et al. Arrayed CRISPR Screening Identifies Novel Targets That Enhance the Productive Delivery of mRNA by MC3-Based Lipid Nanoparticles. SLAS Discov. 2020 Jul;25(6):605-617. doi: 10.1177/2472555220925770. Epub 2020 May 22. PMID: 32441189
  1. Bashore C et al. Targeted degradation via direct 26S proteasome recruitment. Nat Chem Biol. 2023 Jan;19(1):55-63. Epub 2022 Dec 28. PMID: 36577875
  2. Ma S et al. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer. Nat Commun. 2022 Feb 25;13(1):1061. PMID: 35217640
  3. Pal R, Seleem MN. Discovery of a novel natural product inhibitor of Clostridioides difficile with potent activity in vitro and in vivo. PLoS One. 2022 Aug 8;17(8):e0267859. PMID: 35939437
  4. Papandreou A et al. Automated High-Content Imaging in iPSC-derived Neuronal Progenitors. SLAS Discov. 2023 Jan 4:S2472-5552(22)13715-9. PMID: 36610640
  5. Riva L et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020 Oct;586(7827):113-119. Epub 2020 Jul 24. PMID: 32707573
  1. Li J et al DRUG-seq Provides Unbiased Biological Activity Readouts for Neuroscience Drug Discovery. ACS Chem Biol. 2022 Jun 17;17(6):1401-1414. Epub 2022 May 4. PMID: 35508359
  2. Nyffeler J et al. Combining phenotypic profiling and targeted RNA-Seq reveals linkages between transcriptional perturbations and chemical effects on cell morphology: Retinoic acid as an example. Toxicol Appl Pharmacol. 2022 Jun 1;444:116032. Epub 2022 Apr 26. PMID: 35483669
  1. Bousgouni V, Bakal C. Quantitative imaging of single-cell phenotypes in cancer cells cultured on hydrogel surfaces. STAR Protoc. 2022 Dec 15;4(1):101942. doi: 10.1016/j.xpro.2022.101942. Epub ahead of print. PMID: 36525347
  2. Denisova OV et al. Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells. Sci Rep. 2022 Aug 13;12(1):13796. doi: 10.1038/s41598-022-18118-7. PMID: 35963891
  3. Ross-Thriepland D et al. Arrayed CRISPR Screening Identifies Novel Targets That Enhance the Productive Delivery of mRNA by MC3-Based Lipid Nanoparticles. SLAS Discov. 2020 Jul;25(6):605-617. doi: 10.1177/2472555220925770. Epub 2020 May 22. PMID: 32441189

お問い合わせ

ご質問、お見積り依頼は、こちらのフォームよりお気軽にお問い合わせください。

These products are not intended or validated for use in the diagnosis of disease or other conditions.
©2023 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the Stylized Logo, and Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. ECHO is a trademark or registered trademark of Labcyte Inc. in the United States and other countries. Labcyte is a Beckman Coulter company. All other trademarks are the property of their respective owners.